{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:20:32Z","timestamp":1781814032334,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.eururo.2016.02.055","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T17:00:15Z","timestamp":1457370015000},"page":"724-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Pasquale","family":"Rescigno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ferraldeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Kolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafeiris","family":"Zafeiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semini","family":"Sumanasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Jayaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Perez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.02.055_bib0140","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0145","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2016.02.055_bib0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/02841860510029743","article-title":"Endocrine therapy for prostate cancer","volume":"44","author":"Damber","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0155","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2012.12.029","article-title":"Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms","volume":"64","author":"Omlin","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-4295(99)00471-9","article-title":"Clinical states in prostate cancer: toward a dynamic model of disease progression","volume":"55","author":"Scher","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.02.055_bib0165","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0170","first-page":"630","article-title":"Bone metastases: improving the therapeutic index","volume":"21","author":"Scher","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0180","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0185","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","article-title":"Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","volume":"11","author":"Kelly","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0195","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.1995.13.12.2944","article-title":"Evaluation of prostate-specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy","volume":"13","author":"Sridhara","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0200","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0205","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2016.02.055_bib0210","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC): a TAX327 analysis","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0215","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0220","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.02.055_bib0225","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life. Response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.02.055_bib0230","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.ejca.2014.03.015","article-title":"Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"50","author":"Angelergues","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clgc.2014.06.010","article-title":"PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Burgio","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0240","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.02.055_bib0245","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0255","first-page":"3170","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"21","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2016.02.055_bib0260","first-page":"2579","article-title":"Evaluation of clinical decision-making and use of circulating tumor cells (CTCs) by physician treating castration-resistant prostate cancer (CRPC)","volume":"51","author":"Lorente","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2016.02.055_bib0265","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdn062","article-title":"The post-chemotherapy PSA surge syndrome","volume":"19","author":"Thuret","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2016.02.055_bib0270","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jnci\/95.14.1044","article-title":"Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels","volume":"95","author":"Cramer","year":"2003","journal-title":"J Natl Cancer Inst"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816002451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816002451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T10:25:12Z","timestamp":1536920712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816002451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0302283816002451"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.02.055","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.02.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}